Cassava Sciences ended a major clinical trial for its experimental Alzheimer's drug, simufilam, after disappointing results were revealed.
The trial, involving nearly two thousand patients, failed to demonstrate a significant improvement in cognitive function.
Controversy surrounded the drug due to prior questions about the scientific research supporting its development and data integrity.
This outcome significantly impacts Cassava Sciences' future prospects and caused a dramatic drop in their stock value, disappointing investors.
